

THE COMMUNITY AND RESEARCHER ENGAGEMENT (CARE) COMMITTEE

BLOOD NOT BONE MARROW? THE POTENTIAL ROLE FOR BLOOD TESTING TO IMPROVE MULTIPLE MYELOMA DIAGNOSIS AND THERAPY

Understanding the genetic lesions in MM can transform diagnosis, prognosis and treatment. However, this has traditionally relied on single-site bone marrow biopsy that is inadequate for capturing the complexity of this cancer. Please join us as we discuss a new innovative alternative approach called liquid biopsy, which can transform therapeutic options for patients with MM.

Please join us for a Q&A discussion with our speakers after the webinar.


Professor Andrew Spencer is a medical expert in MM at The Alfred. He is a clinician-scientist and leads a research laboratory at the ACBD to develop new therapeutic options for MM patients.

Dr Sridurga Mithraprabhu is a Senior Research Fellow in the Spencer research group and has pioneered the liquid biopsy methodology. She will discuss the utility of this novel concept to improve tumour genome characterisation and therapeutic monitoring in MM.


Myeloma Australia will discuss their association with the Myeloma Research Group.

Dr Nicholas Bingham is a clinical haematologist at The Alfred and a talented PhD student in the Spencer research group. He will discuss the current landscape for diagnosis and therapy in MM.

Mr Henry Blatman was first diagnosed with MM in 2015. He is an active member of Myeloma Australia, advocating for MM awareness and better treatment outcomes for patients. Mr Blatman will present his journey with MM.



Dr Sridurga Mithraprabhu (left),
Dr Nicholas Bingham (middle),
Professor Andrew Spencer (right)
Insert: Mr Henry Blatman



EVENT DETAILS

Date: Thursday 7 October 2021

Time: 5.30 – 7:00pm

Please register at:

https://monash.zoom.us/webinar/register/WN_EttJxJjVSUy0P4Zt-n9yIQ

CONTACT US

Email: acbd.care@monash.edu.au

Twitter: @CCS_cares

Website:
<https://www.monash.edu/medicine/ccs/blood-disease/community-engagement>